(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.



Latest News

ABC: At summit with South, Kim accompanied by sister, generals

Reuters: BRIEF-Hanwang Technology Elects Chairman, Signs Trademark Agreement With Apple

Reuters: FOREX-Dollar at 3-1/2-month high on elevated yields, euro soft after ECB

Daily Mail: Asian shares claw higher after U.S. tech shares bounce

Daily Mail: Cocaine-dealing entrepreneur finds love with solicitor turned pole dancer

WashingtonPost: TV and radio listings: April 27

USA Today: Oakland Raiders use draft pick, trade to bolster offense under new coach Jon Gruden

Wall Street Journal: Follow the Money---and Macron's Vision---to Europe's Future

Wall Street Journal: How Trump Takes On Obstruction

Wall Street Journal: What Does This Moment Demand of Us?

Wall Street Journal: Monkeying Around With Copyright Law

Wall Street Journal: Relaxing Bank Capital Requirements Would Risk Another Crisis

Wall Street Journal: Lincoln's Biblical Lessons of Reconciliation

Wall Street Journal: Senators on the Verge of a Political Breakdown

Wall Street Journal: Road Testing the 2019 Resistance

Wall Street Journal: Victory for the Bitkovs

Wall Street Journal: Europe, Trump and the Iran Deal

Daily Mail: Cardinals QB Rosen: 'Pretty pissed off'

Daily Mail: Guatemalan prison riot leaves 7 dead, 25 injured

Daily Mail: Tunisian women hit campaign trail as equals to men

Daily Mail: Ann Curry says she reported Lauer on behalf of another woman in 2012

NewYorkTimes: RuPaul’s Drag Race: ‘RuPaul’s Drag Race’ Season 10, Episode 6: Merch Madness

USA Today: Rams happy to sit out first round after trading for Cooks